Efficacy and Feasibility of an Intermittent Weight Loss Program.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00395356|
Recruitment Status : Completed
First Posted : November 2, 2006
Last Update Posted : November 2, 2006
The goal of the study is to measure the effect of an approach including phases of active weight loss broken by weight stabilisation periods (named intermittent weight loss) on the metabolic profile.
First, the intermittent weight loss approach will contribute to create an artificial transitory steady state during the weight loss treatment that will help to minimize the adverse effects of the standard approach on muscle mass and resting metabolic rate. Second, despite a comparable fat mass loss, the intermittent weight loss approach will improve the metabolic profile to a greater degree compared to the standard approach. Finally, the intermittent weight loss approach will be associated with less weight regain after the treatment since the beneficial effect on muscle mass and metabolic rate.
|Condition or disease||Intervention/treatment||Phase|
|Obesity||Behavioral: calorie controlled diet||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||20 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Efficacy and Feasibility of an Intermittent Weight Loss Program: A Pilot Study.|
|Study Start Date :||September 2005|
|Study Completion Date :||June 2007|
- Body composition (fat mass and lean body mass): after 0, 5, 10, 15, 20 and 25 weeks, as well as 12-month post-intervention
- Fasting lipids: baseline, 5, 10, 15, 20 and 25 weeks, as well as 12-month post-intervention
- Resting metabolic rate: baseline, 5, 10, 15, 20 and 25 weeks, as well as 12-month post-intervention
- Resting blood pressure: baseline, 5, 10, 15, 20 and 25 weeks, as well as 12-month post-intervention
- OGTT: baseline and 25 weeks
- Dietary habits: baseline,25 weeks and 12-month post-intervention
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00395356
|Institut universitaire de gériatrie de Sherbrooke|
|Sherbrooke, Quebec, Canada, J1H 4C4|
|Principal Investigator:||Martin Brochu, PhD||Université de Sherbrooke|